Juvenile diabetes, now called type 1 diabetes, is caused by the immune system attacking and destroying the insulin-producing cells in the pancreas. Unlike type 2 diabetes, which is driven by lifestyle and metabolic factors, type 1 is an autoimmune disease. About 90% of European children diagnosed with it carry specific inherited gene variants that make them susceptible, but genetics alone don’t pull the trigger. A combination of genetic risk, immune system malfunction, and environmental factors sets the disease in motion, often years before symptoms appear.
The Immune System Attacks the Pancreas
Your pancreas contains clusters of cells called islets, and within those islets are beta cells, which are the only cells in your body that produce insulin. In type 1 diabetes, the immune system mistakes these beta cells for a threat and sends white blood cells to destroy them.
The attack unfolds in waves. A type of immune cell called a CD4 T-cell arrives at the islets first, releasing inflammatory signals that act like an alarm. These signals recruit macrophages (a type of cleanup cell) and activate them into an aggressive state, producing toxic molecules that damage beta cells. The inflammatory environment then draws in CD8 T-cells, which are the immune system’s direct killers. CD8 T-cells physically latch onto beta cells and inject destructive enzymes called perforin and granzyme B, punching holes in the cells and killing them from the inside.
The body does try to shut this process down. Regulatory T-cells attempt to suppress the attack by releasing calming signals, but in people who develop type 1 diabetes, these brakes aren’t strong enough. The destruction continues over months or years until roughly 80 to 90 percent of beta cells are gone, at which point the body can no longer produce enough insulin and blood sugar rises to dangerous levels.
Genetic Risk: The HLA Connection
The strongest genetic risk factor for type 1 diabetes sits in a group of genes called HLA, which control how the immune system identifies threats. Two specific gene variants, known as HLA-DR3 and HLA-DR4, appear in about 90% of European children with the disease. These variants change the way immune cells present proteins to the rest of the immune system, making it more likely that the body will mistake its own beta cell proteins for something foreign.
Having these genes doesn’t guarantee a child will develop diabetes. Most people who carry DR3 or DR4 never do. But carrying both variants together dramatically increases risk. The genes essentially load the gun; something else has to pull the trigger. Researchers have identified over 60 additional gene regions that contribute smaller amounts of risk, many of them involved in immune regulation. This is why type 1 diabetes runs in families but doesn’t follow a simple inheritance pattern. A child with a parent or sibling who has type 1 diabetes faces a higher risk than the general population, yet most children diagnosed have no close family member with the disease.
Environmental Triggers
If genetics set the stage, environmental exposures seem to start the autoimmune process. The leading suspect is viral infection, particularly a family of viruses called enteroviruses. The connection between enterovirus infections and type 1 diabetes has been studied since the 1960s, when researchers noticed that newly diagnosed children had unusually high levels of antibodies against Coxsackie B viruses. Six specific strains of Coxsackie B are now implicated.
The proposed mechanism is called molecular mimicry. A protein on the surface of Coxsackie B viruses looks structurally similar to a protein found on beta cells (an enzyme called GAD65). When the immune system builds a response against the virus, it may accidentally create T-cells that also recognize and attack beta cells. Research has shown that memory CD4 T-cells from a patient exposed to Coxsackie B4 did cross-react with the beta cell protein, supporting this theory.
Vitamin D and Geography
Type 1 diabetes is not evenly distributed around the world. Children living at higher latitudes, where sunlight exposure is lower, develop the disease at significantly higher rates. A study spanning 72 countries found that incidence at latitudes above 40 degrees (roughly the level of New York City or Madrid) was nearly three times higher than in tropical regions: about 14.7 cases per 100,000 children per year compared to 5.0 per 100,000 near the equator. Finland, at 60 degrees north with an average of just 3.2 hours of sunshine per day, has one of the highest rates in the world.
This pattern aligns with vitamin D, which the body produces in response to sunlight. Systematic reviews and meta-analyses have found that adequate vitamin D in early life reduces the risk of type 1 diabetes. Vitamin D plays a role in regulating immune responses, and maintaining sufficient levels may help prevent the immune system from turning against beta cells. Given its low toxicity, some researchers now recommend daily vitamin D supplementation for children at high risk.
Gut Bacteria
The composition of a child’s gut microbiome also appears to matter. Children who test positive for islet autoantibodies, the earliest measurable sign of the autoimmune process, tend to have lower bacterial diversity in their gut and a higher ratio of certain bacterial groups. Two specific species, Bacteroides dorei and Bacteroides vulgatus, accumulate at significantly higher levels in children at high risk. Multiple studies have found that reduced gut bacterial diversity appears before clinical diagnosis, suggesting it plays a role in disease progression rather than being a consequence of it.
How the Disease Develops in Stages
Type 1 diabetes doesn’t appear overnight. A joint scientific statement from JDRF, the Endocrine Society, and the American Diabetes Association defines three stages of progression. In Stage 1, the autoimmune process has started (two or more islet autoantibodies are detectable in the blood) but blood sugar is completely normal and there are no symptoms. A child can remain in this stage for years.
Stage 2 begins when blood sugar control starts to slip. Autoantibodies are still present, and now glucose levels are mildly abnormal on testing, though the child still feels fine. Stage 3 is the point most people think of as “getting diabetes,” when enough beta cells have been destroyed that symptoms appear: excessive thirst, frequent urination, weight loss, and fatigue.
Four specific autoantibodies can be measured in blood tests: antibodies against insulin, against the GAD enzyme, against a protein called IA-2, and against a zinc transporter called ZnT8. The type of autoantibody matters for predicting how quickly a child will progress. Children with IA-2 antibodies alone have about a 40% chance of progressing within a defined follow-up period, compared to roughly 13% for those with only insulin or GAD antibodies.
Rising Rates and Delayed Diagnosis
Type 1 diabetes is becoming more common globally. Between 1990 and 2019, annual new cases in boys rose by nearly 71%, and Europe now has the highest incidence of any region. The reasons for this increase aren’t fully understood, but shifting environmental exposures, changes in early childhood infections, and dietary factors are all under investigation.
One concerning trend is that many children are not diagnosed until they’re already in a medical emergency. About 38.5% of children with newly diagnosed type 1 diabetes present with diabetic ketoacidosis (DKA), a dangerous condition where the body, starved of insulin, begins breaking down fat for energy and produces toxic levels of acid in the blood. That number has climbed from roughly 30% in the early 2000s to over 40% in some recent years. DKA is preventable with earlier detection, which is one reason screening programs using autoantibody blood tests are gaining support for children with a family history or known genetic risk.